Skip Navigation Links

Bookmark and Share
Reistone Biopharma Announces Positive Topline Results from Phase 2 Clinical Trial Evaluating SHR0302, a JAK1 Inhibitor for the Treatment of Moderate-to-Severe Atopic Dermatitis
SHR0302 monotherapy achieved positive results on reaching primary endpoints with statistical significance, delivering significant improvements in skin clearance Both doses were shown to be ...

Full "IntellAsia: Resources" article

Disclaimer | Terms Of Use And Privacy Statement

© Metals News. All rights reserved.